

| Neoadjuvant - Nasopharyngeal | | | | | |
|--|------------------|--|--|--|-----------------|
| PI | CRC | Protocol #/Title | Mechanism | Primary In/Ex Criteria | Status |
| Dr. Nabar | Natalie Arechiga | NRG-HN001 Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) | Adjuvant Cisplatin/5FU vs Gemcitabine/Paclitaxel | Must have detectable EBV DNA Biopsy proven stage II-IVB nasopharyngeal cancer with no distant metastasis Must not have prior invasive malignancy | Open to accrual |
| NeoAdjuvant - Squamous Cell Carcinoma of Head and Neck - Oropharyngeal | | | | | |
| PI | CRC | Protocol #/Title | Mechanism | Primary In/Ex Criteria | Status |
| Dr. Chen | Natalie Arechiga | UCI 22-132: De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx | IMRT | Inclusion: Pathologically proven diagnosis of HPV-positive OPSCC. HPV-positivity will be defined as tumors that are p16-positive by immunohistochemistry Clinical stage I, II, or III disease (AJCC Eighth Edition) Exclusion: Patients who have had initial surgical treatment other than the diagnostic biopsy of the primary site or nodal sampling of the neck disease are excluded; | Open to accrual |
| Adjuvant - Squamous Cell Carcinoma of Head and Neck | | | | | |
| PI | CRC | Protocol #/Title | Mechanism | Primary In/Ex Criteria | Status |
| Recurrent and/or Metastatic Squamous Cell Carcinoma | | | | | |
| PI | CRC | Protocol #/Title | Mechanism | Primary In/Ex Criteria | Status |